Check Cap

Check Cap Debt/EBITDA

The Total Debt to EBITDA Ratio of Check Cap (MBAI) as of Oct 9, 2026 is -0.01. In the previous year, Total Debt to EBITDA Ratio was -0.01 — a change of 27.85% (lower).

Debt/EBITDA

-0.01

YoY

27.85%

Last updated:

Total Debt to EBITDA Ratio of Check Cap is 2025 -0.01 . Total Debt to EBITDA Ratio of Check Cap was 2024 -0.01 . It decreases by 27.85% lower compared to the previous year.

The Check Cap Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2021
-0.07 USD
Jan 1, 2022
-0.05 USD
Jan 1, 2024
-0.01 USD
Jan 1, 2025
-0.01 USD
The Check Cap Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.01+27.85%
-0.01-89.26%
-0.05-25.71%
-0.07—
Access this data via the Eulerpool API

Check Cap Stock analysis

What does Check Cap do? Check Cap Ltd is an international biotech company specializing in the development of non-invasive diagnostic technologies for early detection of colon cancer. The company is headquartered in Israel and was founded in 2004. Check Cap is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Check Cap stock

Total Debt to EBITDA Ratio of Check Cap is -0.01 in 2025.

Total Debt to EBITDA Ratio of Check Cap changed from -0.01 to -0.01, representing a 27.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Check Cap since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Check Cap with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Check Cap

All Key Metrics — Check Cap